Grifols reported EUR6.21B in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
Alaunos Therapeutics USD 1.29M 865K Mar/2026
Arca Biopharma USD 486.72M 17.72M Mar/2026
aTyr Pharma USD 57.93M 82.05M Mar/2026
Bio Path USD -8.49M 482K Mar/2026
Brainstorm Cell Therapeutics USD -11.01M 1.02M Mar/2026
Capricor Therapeutics USD 278.7M 27.09M Mar/2026
Cara Therapeutics USD 20.95M 6.92M Dec/2025
Esperion Therapeutics USD -307.93M 5.97M Mar/2026
GlaxoSmithKline GBP 17.42B 1.05B Mar/2026
Grifols EUR 6.21B 133.12M Dec/2025
Immunic USD 151.23M 157.91M Mar/2026
Infinity Pharmaceuticals USD -37.41M 9.08M Jun/2023
Minerva Neurosciences USD -140.75M 106.17M Dec/2025
Nektar Therapeutics USD 89.83M 4.75M Dec/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
TherapeuticsMD USD 27.67M 990K Jun/2024